FINNCURE

FINNCURE is a Finnish biotech company focusing on solutions against a wide range of diseases. Synthetic carrier particles (e.g., virus-like particles) are receiving a lot of attention across the world. We are strongly positioned in that space. Our micro- and nanoparticle technology platform enables a wide range of solutions for medical unmet needs. Those enable effective prevention and treatments of diseases by disabling transmission, stimulating the immune system, and delivering therapeutic and other compounds to the target tissues. During the past couple of years, scientific communities across the world have proven in independent scientific studies - published in major scientific journals - that major cornerstones of our technologies really work and match with globally acknowledged clinical unmet needs. Our preclinical studies have progressed according to our plans, and results have been excellent. Target delivery is one of our cornerstones. Our particles can carry in practice any active pharmaceutical ingredients (API) to targeted cells and tissues with superior accuracy and bioavailability. Our manufacturing technology is also unique. The way of manufacturing lipid particles with extreme size accuracy and high volumes, with customers API, is proven and ready to be tested by customers. During summer 2025, we are ready to disclose more about our technologies and IP portfolio. We have already four issued patents (e.g., for targeted therapies) in the U.S., and the newest (manufacturing) got a notice of allowance. The next ones are nicely in the pipeline. Our team is a combination of experienced professionals in nano medicine, drug development, medical devices, regulation, global business and finance, and contract law. Our advisor in IP strategy and portfolio management is Knobbe Martens LLP (Irvine, CA, USA). It is a Tier 1 U.S. IP law firm in the health tech and life science space. You can contact us here at LinkedIn. Stay tuned for exciting news…